King warned on Embeda VNRs

Share this article:

VNRs for King's ostensibly abuse-resistant pain drug Embeda drew an FDA warning letter.

The agency said two VNRs omitted or minimized risks, including those featured in the drug's “extensive” boxed warning, and failed to present limitations to the approved indication. Moreover, the letter said King presented misleading claims – among them, about the drug's alleged but clinically unsubstantiated abuse-resistant properties.  DDMAC said King agreed to pull the VNRs in August.

DDMAC demanded the company furnish a list of materials it has pulled, and that it disseminate corrective messaging.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...